Intellipharmaceutics (IPCI) Not Required to Conduct Rexista Oxycodone XR Phase 3 if Oxycontin Bioequivalence Demonstrated

May 21, 2015 8:04 AM

Intellipharmaceutics International (NASDAQ: IPCI) announced that the United States Food and Drug Administration ("FDA") provided the Company with notification regarding ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found